AETHLON MEDICAL INC
(NASDAQ: AEMD)

Aethlon Medical, Inc. is a medical device company, which creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are secreted by tumors to prevent the immune system from rejecting the tumors. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based products to diagnose and monitor neurological disorders and cancer. Additionally, the Company operates under two Department of Defense contracts related to a program entitled Dialysis-Like Therapeutics.

1.430

+0.010 (+0.70%)
Range - - 1.450   (-%)
Open -
Previous Close 1.420
Bid Price 0.317
Bid Volume 11
Ask Price 0.318
Ask Volume 8
Volume 2,296
Value -
Remark
Delayed prices. Updated at 19 Apr 2024 02:39.
Data powered by
View All Events

About AETHLON MEDICAL INC

Aethlon Medical, Inc. is a medical device company, which creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are secreted by tumors to prevent the immune system from rejecting the tumors. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based products to diagnose and monitor neurological disorders and cancer. Additionally, the Company operates under two Department of Defense contracts related to a program entitled Dialysis-Like Therapeutics.

Loading Chart...

Please login to view stock data and analysis